anticancer/infarction

FIELD OF THE INVENTION The present invention relates to agents for eliminating active oxygen and free radicals containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an effective component. The reduction and elimination of free radicals and activated oxygen in living

This invention relates to a family of fluorinated aryl, heteroaryl, O-aryl and O-heteroaryl glycoside compounds, the process for their preparation, as well as the application of same in the pharmaceutical or cosmetic fields, in particular for the treatment or prevention of diabetes and obesity, and

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

The present invention relates to antibodies that bind CD47 and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor. CD47 is a cell surface receptor comprised of an extracellular IgV set domain, a 5 membrane spanning

INCORPORATION OF SEQUENCE LISTING The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled, "VLX0001-201CIP2 US_SequenceListing", created on Jun. 11, 2015, which is 168,755 bytes in size. The information in the

BACKGROUND The present disclosure relates to antibodies that bind CD47, including that of humans and other mammalian species, and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor. CD47 is a cell surface receptor

The present invention relates to an animal cell adhesion inhibitory composition which comprises a 4oxo-3-quinolinecarboxylic acid or 4oxo-3-naphthyridinecarboxylic acid derivative possessing cell adhesion inhibitory activity, a novel 4-oxo-3-quinolinecarboxylic acid derivative and a method of

The present invention relates to an animal cell adhesion inhibitory composition which comprises a 4-oxo-3-quinolinecarboxylic acid or 4-oxo-3-naphthyridinecarboxylic acid derivative possessing cell adhesion inhibitory activity, a novel 4-oxo-3-quinolinecarboxylic acid derivative and a method of

The present invention relates to an animal cell adhesion inhibitory composition which comprises a 4-oxo-3-quinolinecarboxylic acid or 4-oxo-3-naphthyridinecarboxylic acid derivative possessing cell adhesion inhibitory activity, a novel 4-oxo-3-quinolinecarboxylic acid derivative and a method of

BACKGROUND OF THE INVENTION The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the

TECHNICAL FIELD The present invention relates to a pyridine derivative having an ability to act as a neurotrophic factor and a salt thereof. BACKGROUND ART It has been suggested that in Alzheimer's disease, which has recently been increasing in prevalence, degeneration and dysfunction of cholinergic

BACKGROUND OF THE INVENTION The invention relates the field of N-(4-carbamimidophenyl)glycineamide derivatives. In particular, the invention relates to novel N-(4-carbamimidophenyl) glycineamide derivatives that are useful for inhibiting the coagulation factors Xa, IXa, and thrombin induced by the

All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to